| Literature DB >> 28467926 |
Estelle Grasset1, Anthony Puel1, Julie Charpentier1, Xavier Collet1, Jeffrey E Christensen1, François Tercé1, Rémy Burcelin2.
Abstract
Glucagon-like peptide-1 (GLP-1)-based therapies control glycemia in type 2 diabetic (T2D) patients. However, in some patients the treatment must be discontinued, defining a state of GLP-1 resistance. In animal models we identified a specific set of ileum bacteria impairing the GLP-1-activated gut-brain axis for the control of insulin secretion and gastric emptying. Using prediction algorithms, we identified bacterial pathways related to amino acid metabolism and transport system modules associated to GLP-1 resistance. The conventionalization of germ-free mice demonstrated their role in enteric neuron biology and the gut-brain-periphery axis. Altogether, insulin secretion and gastric emptying require functional GLP-1 receptor and neuronal nitric oxide synthase in the enteric nervous system within a eubiotic gut microbiota environment. Our data open a novel route to improve GLP-1-based therapies.Entities:
Keywords: autonomic nervous system; enteric neurons; gut brain axis; incretins; metabolic diseases; microbiota; nitric oxide
Mesh：
Substances：
Year: 2017 PMID： 28467926 DOI： 10.1016/j.cmet.2017.04.013
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287